ATE142885T1 - Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern - Google Patents

Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern

Info

Publication number
ATE142885T1
ATE142885T1 AT92915210T AT92915210T ATE142885T1 AT E142885 T1 ATE142885 T1 AT E142885T1 AT 92915210 T AT92915210 T AT 92915210T AT 92915210 T AT92915210 T AT 92915210T AT E142885 T1 ATE142885 T1 AT E142885T1
Authority
AT
Austria
Prior art keywords
lymphocytes
antibodies
short
increase
vivo activity
Prior art date
Application number
AT92915210T
Other languages
English (en)
Inventor
Augusto C Ochoa
Cynthia Loeffler
Walter Urba
Dan L Longo
Original Assignee
Augusto C Ochoa
Cynthia Loeffler
Walter Urba
Dan L Longo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augusto C Ochoa, Cynthia Loeffler, Walter Urba, Dan L Longo filed Critical Augusto C Ochoa
Application granted granted Critical
Publication of ATE142885T1 publication Critical patent/ATE142885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT92915210T 1991-07-10 1992-07-10 Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern ATE142885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72810791A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
ATE142885T1 true ATE142885T1 (de) 1996-10-15

Family

ID=24925447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92915210T ATE142885T1 (de) 1991-07-10 1992-07-10 Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern

Country Status (12)

Country Link
US (1) US5316763A (de)
EP (1) EP0593625B1 (de)
JP (1) JP3507489B2 (de)
AT (1) ATE142885T1 (de)
AU (1) AU674128B2 (de)
CA (1) CA2111564A1 (de)
DE (1) DE69213943T2 (de)
IE (1) IE922233A1 (de)
IL (1) IL102460A (de)
MX (1) MX9204077A (de)
WO (1) WO1993000918A1 (de)
ZA (1) ZA925155B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
WO1995020649A1 (en) * 1994-01-27 1995-08-03 Cellcor, Inc. Ex vivo activation of immune cells
AU2604895A (en) * 1994-05-31 1995-12-21 Dan L. Longo Short-term anti-cd3 stimulation of lymphocytes to increase their (in vivo) activity
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
WO1996040176A1 (en) * 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1998014206A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
JP6074916B2 (ja) * 2012-05-22 2017-02-08 東洋製罐グループホールディングス株式会社 細胞活性化方法、及び細胞培養方法
CN107502589A (zh) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175036D1 (en) * 1980-10-02 1986-09-04 Hooper Trading Co Nv A t-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
DE3687014T2 (de) * 1985-05-01 1993-04-01 Asahi Chemical Ind Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
JPH03503844A (ja) * 1988-04-15 1991-08-29 リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド Ｌａｋ細胞サイトトキシン
AU4485089A (en) * 1988-10-21 1990-05-14 Brigham And Women's Hospital Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Also Published As

Publication number Publication date
MX9204077A (es) 1994-06-30
IL102460A0 (en) 1993-01-14
DE69213943T2 (de) 1997-04-10
IE922233A1 (en) 1993-01-13
AU674128B2 (en) 1996-12-12
JPH07502486A (ja) 1995-03-16
EP0593625A4 (de) 1994-11-02
EP0593625A1 (de) 1994-04-27
DE69213943D1 (de) 1996-10-24
AU2300592A (en) 1993-02-11
ZA925155B (en) 1993-04-28
JP3507489B2 (ja) 2004-03-15
WO1993000918A1 (en) 1993-01-21
CA2111564A1 (en) 1993-01-21
IL102460A (en) 2001-08-26
US5316763A (en) 1994-05-31
EP0593625B1 (de) 1996-09-18

Similar Documents

Publication Publication Date Title
ATE142885T1 (de) Kurzzeitige stimulierung von lymphozyten mit anti-cd3 antikörpern um ihre in vivo aktivität zu steigern
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
GR3022969T3 (en) Products for the treatment of endotoxic shock in a mammal
ATE147633T1 (de) Immunhilfsmittel aus liposome enthaltend lymphokin il -2
EP0702563A4 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DK0504177T3 (da) IL-11, et pattedyrcytokin
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
DE3887031D1 (de) Verabreichungsform für einen Antagonisten von Gamma-Interferon zur Bekämpfung einer GHK-assoziierten Autoimmunerkrankung.
ES2144426T3 (es) Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
MY135673A (en) Monoclonal antibodies for inducing tolerance
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
Tanaka et al. Expression of IL-1 receptors on human peripheral B cells.
Lamon et al. Antibodies to homologous RNA in the rabbit following stimulation by exogenous RNA
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
SU563390A1 (ru) В жущее
Scheibenbogen et al. Phase II study of intermittent low-dose IFN-gamma in metastatic renal cell cancer
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
DE69131248D1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase
KR880011336A (ko) IL-1α 유도체 및 약제
IL73281A0 (en) Purified antigen isolated from sera of leukemia and lymphoma patients,novel antibodies to said antigen,methods of preparing same and diagnostic and therapeutic methods employing said antibody